NEWS & EVENTS

Latest news and upcoming events

Memo Therapeutics increases Series C financing to CHF 45 million
07 May 2024

Memo Therapeutics increases Series C financing to CHF 45 million

Upcoming events

  • Bio€quity Europe
    14 - 16 May 2024,
    San Sebastián

    download

  • AseBio Investor Day 2024
    15 May 2024,
    San Sebastián

    download

  • ESMO Congress 2024
    13 - 19 September 2024,
    Barcelona

    download
VarmX appoints Paul Roos as Chief Financial Officer<
31 Jan 2023

VarmX appoints Paul Roos as Chief Financial Officer

Paul has a wealth of experience in the international life sciences industry and investment banking
Ysios Capital strengthens its team with internal promotions and a new Venture Partner<
19 Jan 2023

Ysios Capital strengthens its team with internal promotions and a new Venture Partner

These appointments add operational capacities supporting Ysios’ mission to build leading life sciences companies.
The Lancet Neurology publishes results from Minoryx Therapeutics Phase 2/3 ADVANCE clinical trial of leriglitazone in X-linked Adrenoleukodystrophy<
19 Jan 2023

The Lancet Neurology publishes results from Minoryx Therapeutics Phase 2/3 ADVANCE clinical trial of leriglitazone in X-linked Adrenoleukodystrophy

Leriglitazone was well tolerated, and significant benefit was shown through clinically meaningful myelopathy endpoints and reduced progression of cerebral lesions
Adcendo ApS Announces License Agreement with Duality Biologics on Next-generation ADC Platform<
09 Jan 2023

Adcendo ApS Announces License Agreement with Duality Biologics on Next-generation ADC Platform

Agreement based on synergies between Adcendo and Duality in generating breakthrough ADCs in hard-to-treat cancers
LAVA Therapeutics Announces Appointment of New Directors to the Board<
06 Jan 2023

LAVA Therapeutics Announces Appointment of New Directors to the Board

Peter A. Kiener, DPhil and Mary E. Wadlinger to Join LAVA Board.
NorthSea Therapeutics provides clinical update reflecting progress across NASH and metabolic disorders programmes<
05 Jan 2023

NorthSea Therapeutics provides clinical update reflecting progress across NASH and metabolic disorders programmes

Top line results of Phase 2b ICONA trial with lead programme icosabutate for NASH  expected in Q1 2023  
NorthSea Therapeutics appoints Morris J. Birnbaum to the Board<
21 Dec 2022

NorthSea Therapeutics appoints Morris J. Birnbaum to the Board

Former Pfizer Internal Medicine CSO joins the Board as an independent board member
Inbiomotion appoints Ralf van den Berg as Chief Operating Officer<
20 Dec 2022

Inbiomotion appoints Ralf van den Berg as Chief Operating Officer

Ralf van den Berg will drive Inbiomotion in his aim to position MAFTEST® for routine characterization of breast cancer tumors.
GlyTherix and Adcendo Announce Agreement for Development of Antibody Drug Conjugate<
19 Dec 2022

GlyTherix and Adcendo Announce Agreement for Development of Antibody Drug Conjugate

Under the terms of the agreement, Adcendo’s planned pre-clinical ADC development program will be based on GlyTherix’s lead anti-GPC-1 monoclonal antibody, Miltuximab®.
SparingVision’s lead asset SPVN06 clears IND application in the US for the treatment of retinitis pigmentosa<
01 Dec 2022

SparingVision’s lead asset SPVN06 clears IND application in the US for the treatment of retinitis pigmentosa

First safety data expected in 2023 with full read-out expected in 2025

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.

Bitplex 360 Кракен даркнет кракен даркнет Blacksprut Blacksprut Кракен ссылка кракен ссылка